EGFR and non-small cell lung carcinoma: Gefitinib has been registered for the therapy of advanced NSCLC harbouring activating EGFR mutations in the tyrosine kinase domain, the most frequent being L858R in exon 21 and Del (746–750) in exon 19 [6].